By Anna Rose Welch, editor, Biosimilar Development
In this first of a two-part article based on our discussion, a payer and employer coalition director highlight some of the payer and employer-centric discussions that are being had today to both improve biosimilar access and navigate a system that has not been friendly to lower-cost competition thus far.
This is the second article in a two-part series reviewing the MHRA’s publication of the GMP deficiencies for drug product published in October 2019. Part 1 identified and evaluated the critical and major deficiencies. Part 2 presents the 10 most frequently cited paragraphs for the 10 chapters and annexes with the most frequently cited deficiencies.
Epitope binning immunoassays using surface plasmon resonance (SPR) can and should be deployed in the development of new potential drug candidates. This article discusses how SPR is used to characterize closely related “bins” of mAbs targeting the same epitope of the target protein and how the selection process is used to develop new vaccines, therapeutic antibodies, and diagnostic tools.
ISR conducted approximately two dozen individual pieces of market research for syndication in 2019. This webinar will summarize many of the important learnings from these projects, providing real, usable data for 2020 activities.
We are thrilled to offer top-tier content and share global thought leadership in one customizable program at the DIA 2020 Global Annual Meeting. DIA 2020 is more than a meeting: It’s fueled by our common goal to bring life-saving medicines to patients. DIA 2020 consists of 250+ sessions woven through 13 unique tracks with nine different learning formats, ensuring all have the best learning experience.